GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 15, 2003, 14:50:12 ; Search time 42 Seconds
(without alignments)
1171.553 Million cell updates/sec

Title: US-09-831-805A-6
Perfect score: 1635
Sequence: 1 MALRRPPRLRLCARLPDFFL.....VNYIRTDEEGDFRHKSSFVI 310

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1635	100.0	310	21	AAY96294	Human IGFAM-6 immu
2	1629	99.6	310	21	AAB27276	Human confluency r
3	1629	99.6	310	21	AAB33457	Human PRO1868 prot
4	1629	99.6	310	21	AAY96735	PRO1868, an A33 an
5	1629	99.6	310	22	AAM93323	Human polypeptide,
6	1629	99.6	310	22	AAM93905	Human polypeptide,
7	1629	99.6	310	22	AAU12440	Human PRO1868 poly
8	1629	99.6	310	22	AAB80272	Human PRO1868 prot
9	1629	99.6	310	22	AAB80383	Secreted protein e
10	1629	99.6	310	22	AAB80408	Secreted protein e
11	1629	99.6	310	22	AAB80409	Secreted protein e
12	1629	99.6	310	23	ABG31401	Human PRO1868 poly
13	1629	99.6	310	23	ABG91361	Novel human secret
14	1629	99.6	310	23	ABG92709	Human secreted pro
15	1629	99.6	310	23	ABG65296	Human albumin fusi
16	1629	99.6	310	23	ABG65297	Human albumin fusi
17	1629	99.6	310	23	ABG65298	Human albumin fusi
18	1629	99.6	310	23	ABB95553	Human angiogenesis
19	1629	99.6	310	23	ABB84947	Human PRO1868 prot
20	1629	99.6	310	24	ABU69682	Novel human secret
21	1629	99.6	310	24	ABU71505	Human PRO polypept
22	1629	99.6	310	24	ABU71951	Human secreted/tra
23	1629	99.6	310	24	ABU66838	Human PRO polypept
24	1629	99.6	310	24	ABU67114	Human secreted/tra
25	1629	99.6	310	24	ABU67405	Human secreted pro
26	1629	99.6	310	24	ABU59919	Novel secreted and
27	1629	99.6	310	24	ABU60813	Human secreted/tra
28	1629	99.6	310	24	ABU64559	Human secreted/tra
29	1629	99.6	310	24	ABG73314	Human PRO1868 poly
30	1629	99.6	310	24	ABP71277	Human junctional a
31	1629	99.6	310	24	ABU54407	Human secreted/tra
32	1629	99.6	311	21	AAB38333	Human secreted pro
33	1629	99.6	311	21	AAB38383	Human secreted pro
34	1629	99.6	311	21	AAB38384	Human secreted pro
35	1629	99.6	339	22	AAB80431	Gene #13 associate
36	1620	99.1	329	23	ABP41902	Human ovarian anti
37	1613	98.7	310	24	AAO16453	Human junctional a
38	1490	91.1	285	21	AAB39254	Human secreted pro
39	1475	90.2	321	23	ABB06037	Human NS protein s
40	1401	85.7	310	21	AAB27272	Human confluency r
41	1401	85.7	310	21	AAB27278	Murine confluency
42	1066	65.2	361	22	ABG22401	Novel human diagno
43	878	53.7	291	22	ABG04645	Novel human diagno
44	878	53.7	404	22	ABG12109	Novel human diagno
45	488	29.8	298	24	AAO16452	Human junctional a

ALIGNMENTS

RESULT 1
AAY96294
ID AAY96294 standard; protein; 310 AA.
XX
AC AAY96294;
XX
DT 16-AUG-2000 (first entry)
XX
DE Human IGFAM-6 immunoglobulin.
XX
KW Human; immunoglobulin; IGFAM-6; IGFAM; immune disorder; cancer;
KW infection; inflammation; haematopoiesis; AIDS; allergy.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..30
FT /label= signal_peptide
FT Protein 31..310
FT /label= IGFAM-6
FT Domain 46..117
FT /label= Ig_domain
FT Domain 153..221
FT /label= Ig_domain
FT Domain 238..260
FT /label= transmembrane_domain
XX
PN WO200029583-A2.
XX
PD 25-MAY-2000.
XX
PF 19-NOV-1999; 99WO-US27566.

XX
PR 19-NOV-1998; 99US-0113635.
PR 22-DEC-1998; 98US-0113635.
PR 07-APR-1999; 99US-0128194.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Yue H, Tang YT, Corley NC, Guegler KJ, Gorgone GA, Baughn MR;
PI Lu DAM, Lal P, Hillman JL, Yang J;
XX
DR WPI; 2000-387796/33.
DR N-PSDB; AAA27386.
XX
PT Immunoglobulin superfamily proteins, the agonist and antagonist of the
PT protein is useful for preventing and treating disorders associated with
PT altered levels of the protein such as cancer, immune system disorders
PT -
XX
PS Claim 1; Page 82-83; 105pp; English.
XX
CC The present sequence is the human immunoglobulin superfamily protein
CC IGFAM-6. Its gene was isolated from a cDNA library of leg
CC tissue. It is expressed in reproductive, nervous and
CC cardiovascular tissue, where cancer and inflammation are common. The
CC gene, protein, its antibodies, agonists and antagonists are suitable for
CC diagnosing and treating many diseases, including cancer, immune system
CC disorders (such as inflammation, AIDS, allergies, anaemia,
CC arteriosclerosis, asthma, atherosclerosis, cholecystitis, Crohn's
CC disease, diabetes mellitus, emphysema, Graves' disease, hepatitis,
CC multiple sclerosis, psoriasis, rheumatoid arthritis, scleroderma,
CC systemic lupus erythematosus and ulcerative colitis), complications of
CC cancer, haemodialysis and extracorporeal circulation, trauma and
CC haematopoietic cancer (such as leukaemia) and infections caused by
CC bacteria, viruses, fungi or parasites.
XX
SQ Sequence 310 AA;

Query Match 100.0%; Score 1635; DB 21; Length 310;
Best Local Similarity 100.0%; Pred. No. 2.2e-133;
Matches 310; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 2
AAB27276
ID AAB27276 standard; Protein; 310 AA.
XX
AC AAB27276;
XX
DT 23-FEB-2001 (first entry)

XX
DE Human confluency regulated adhesion molecule 1 #2.
XX
KW Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;
KW inflammation; cancer; wound; angiogenesis; human;
KW confluency regulated adhesion molecule 1; CRAM-1; JAM-2.
XX
OS Homo sapiens.
XX
PN WO200053749-A2.
XX
PD 14-SEP-2000.
XX
PF 13-MAR-2000; 2000WO-EP02219.
XX
PR 11-MAR-1999; 99EP-0200746.
XX
PA (RMFD-) RMF DICTAGENE SA.
XX
PI Imhof BA, Aurrand-Lions M;
XX
DR WPI; 2000-587436/55.
DR N-PSDB; AAA95306.
XX
PT Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (CRAM-1 or
PT CRAM-2) polypeptide, useful for treatment of tumors, inflammation
PT reactions and modulating vascular permeability -
XX
PS Claim 2; Fig 6; 59pp; English.
XX
CC The present sequence is the human confluency regulated adhesion molecule
CC 1 (CRAM-1, also known as JAM-2). CRAM-1 is one of the vascular adhesion
CC proteins of the immunoglobulin superfamily (Ig Sf). The CRAM-1 protein
CC and coding sequence can be used in the treatment of cancer, inflammation,
CC to modulate cell-cell interactions and angiogenesis, and in the
CC modulation of wound healing.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 21; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 3
AAB33457
ID AAB33457 standard; Protein; 310 AA.
XX
AC AAB33457;

XX
DT 29-JAN-2001 (first entry)
XX
DE Human PRO1868 protein UNQ859 SEQ ID NO:193.
XX
KW Human; immune related disease; diagnosis; antiinflammatory; cardiant;
KW dermatological; antiarthritic; antirheumatic; immunosuppressive;
KW haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
KW antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;
KW antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis;
KW osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;
KW idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;
KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;
KW autoimmune thrombocytopaenia; immune-mediated renal disease;
KW demyelinating disease; hepatobiliary disease; Whipple's disease;
KW inflammatory bowel disease; gluten-sensitive enteropathy;
KW autoimmune disease; immune-mediated skin disease; allergic disease;
KW immunological disease; transplantation associated disease;
KW graft rejection; graft-versus-host-disease.
XX
OS Homo sapiens.
XX
PN WO200053758-A2.
XX
PD 14-SEP-2000.
XX
PF 02-MAR-2000; 2000WO-US05841.
XX
PR 08-MAR-1999; 99WO-US05028.
PR 10-MAR-1999; 99US-0123618.
PR 12-MAR-1999; 99US-0123957.
PR 23-MAR-1999; 99US-0125775.
PR 12-APR-1999; 99US-0128849.
PR 20-APR-1999; 99WO-US08615.
PR 28-APR-1999; 99US-0131445.
PR 04-MAY-1999; 99US-0132371.
PR 14-MAY-1999; 99US-0134287.
PR 02-JUN-1999; 99WO-US12252.
PR 23-JUN-1999; 99US-0141037.
PR 20-JUL-1999; 99US-0144758.
PR 26-JUL-1999; 99US-0145698.
PR 28-JUL-1999; 99US-0146222.
PR 01-SEP-1999; 99WO-US20111.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-OCT-1999; 99US-0162506.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30999.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;
PI Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;
PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Yan M;
XX
DR WPI; 2000-572271/53.
DR N-PSDB; AAC58622.
XX
PT Sixty four PRO polypeptides, useful in the diagnosis and treatment of
PT immune related disorders, e.g. systemic lupus erythematosis, rheumatoid
PT arthritis, osteoarthritis, thyroiditis and diabetes mellitus -
XX
PS Claim 33; Fig 88; 309pp; English.
XX
CC The present invention describes sixty four human PRO proteins which can
CC be used in the treatment of immune related diseases. The human PRO
CC proteins, anti-PRO antibodies, agonists and antagonists are useful for
CC treating and diagnosing immune related disorders. The disorders are
CC selected from systemic lupus erythematosus, rheumatoid arthritis,
CC osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,
CC systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's
CC syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic
CC anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,
CC immune-mediated renal disease, demyelinating diseases of the central
CC and peripheral nervous systems, hepatobiliary diseases, inflammatory
CC bowel disease, gluten-sensitive enteropathy and Whipple's disease,
CC autoimmune or immune-mediated skin diseases, allergic diseases,
CC immunological diseases of the lung, and transplantation associated
CC diseases including graft rejection and graft-versus-host-disease.
CC AAC58397 to AAC58578 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAC58579 to AAC58642 and
CC AAB33414 to AAB33477 represent human PRO polynucleotide and protein
CC sequences given in the exemplification of the present invention.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 21; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 4
AAY96735
ID AAY96735 standard; Protein; 310 AA.
XX
AC AAY96735;
XX
DT 26-SEP-2000 (first entry)
XX
DE PRO1868, an A33 antigen homologue.
XX
KW PRO1868; A33 antigen; secreted protein; transmembrane protein;
KW anti-inflammatory; cytostatic; recombinant production; gene therapy.

```
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..30
FT                   /label= Signal_peptide
FT   Modified-site   26..31
FT                   /note= "N-myristoylation site"
FT   Modified-site   69..77
FT                   /note= "Tyrosine kinase phosphorylation site"
FT   Modified-site   104..107
FT                   /note= "N-glycosylation site"
FT   Modified-site   106..109
FT                   /note= "Casein kinase II phosphorylation site"
FT   Modified-site   107..110
FT                   /note= "cAMP- and cGMP-dependent protein kinase
FT                          phosphorylation site"
FT   Modified-site   192..195
FT                   /note= "N-glycosylation site"
FT   Modified-site   215..220
FT                   /note= "N-myristoylation site"
FT   Modified-site   226..231
FT                   /note= "N-myristoylation site"
FT   Domain          243..263
FT                   /label= Transmembrane_domain
FT   Modified-site   243..248
FT                   /note= "N-myristoylation site"
FT   Modified-site   244..249
FT                   /note= "N-myristoylation site"
FT   Modified-site   262..267
FT                   /note= "N-myristoylation site"
FT   Modified-site   296..299
FT                   /note= "Casein kinase II phosphorylation site"
XX
PN   WO200036102-A2.
XX
PD   22-JUN-2000.
XX
PF   01-DEC-1999;   99WO-US28634.
XX
PR   16-DEC-1998;   98US-0112851.
PR   16-DEC-1998;   98US-0113145.
PR   22-DEC-1998;   98US-0113511.
PR   12-JAN-1999;   99US-0115558.
PR   12-JAN-1999;   99US-0115565.
PR   12-JAN-1999;   99US-0115733.
PR   09-FEB-1999;   99US-0119341.
PR   10-FEB-1999;   99US-0119537.
PR   12-FEB-1999;   99US-0119965.
PR   02-JUN-1999;   99WO-US12252.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Botstein D,  Desnoyers L,  Ferrara N,  Fong S,  Gao W,  Goddard A;
PI   Gurney AL,  Pan J,  Roy MA,  Stewart TA,  Tumas D,  Watanabe CK;
PI   Wood WI;
XX
DR   WPI; 2000-431586/37.
DR   N-PSDB; AAA51265.
XX
PT   Isolated nucleic acid molecule encodes a PRO polypeptide which is a
PT   transmembrane polypeptide
XX
PS   Claim 1; Fig 14; 154pp; English.
XX
CC   This is PRO1868, a putative homologue of A33 antigen, a known
CC   colorectal cancer-associated marker. The invention concerns novel
CC   secreted and transmembrane proteins, designated PRO polypeptides. The
CC   cDNA and gene sequences are useful in the recombinant production of PRO
CC   polypeptides, as a hybridization probe to screen libraries to isolate
CC   cDNAs with sequence identity to PRO polypeptides or to map the gene
CC   encoding the PRO polypeptides and analyzing genetic disorders. The
CC   cDNA/gene can also be used to produce transgenic animals useful for the
CC   development and screening of therapeutically useful reagents. They can
CC   also be used in gene therapy, e.g. to replace a defective gene.
XX
SQ   Sequence   310 AA;

  Query Match             99.6%;  Score 1629;  DB 21;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 7.2e-133;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 5
AAM93323
ID   AAM93323 standard; Protein; 310 AA.
XX
AC   AAM93323;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human polypeptide, SEQ ID NO: 2845.
XX
KW   Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS   Homo sapiens.
XX
PN   EP1130094-A2.
XX
PD   05-SEP-2001.
XX
PF   07-JUL-2000; 2000EP-0114089.
XX
PR   08-JUL-1999;   99JP-0194486.
PR   11-JAN-2000; 2000JP-0118774.
PR   02-MAY-2000; 2000JP-0183765.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Nishikawa T,  Isogai T,  Hayashi K,  Ishii S,  Kawai Y;
PI   Wakamatsu A,  Sugiyama T,  Nagai K,  Kojima S,  Otsuki T,  Koga H;
XX
DR   WPI; 2001-524255/58.
DR   N-PSDB; AAK94243.
XX
PT   830 Primers useful for synthesizing full length cDNA clones and their
PT   use in genetic manipulation -
XX
PS   Claim 8; SEQ ID NO 2845; 1380pp + sequence listing; English.
XX
CC   The invention relates to primers for synthesising full length cDNA
CC   clones. 830 cDNA molecules encoding a human protein have been
```

```
CC   isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC   molecules have been determined. Primers for synthesising the full length
CC   cDNA are useful for clarifying the function of the protein encoded by
CC   the cDNA. The full length clones were obtained by construction of full
CC   length enriched cDNA libraries that were synthesised by the oligo-capping
CC   method. The primers enable the production of the full length cDNA easily
CC   without any special methods. The present sequence is a polypeptide
CC   encoded by a full length human cDNA of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in CD-ROM format directly from EPO.
XX
SQ   Sequence   310 AA;

  Query Match             99.6%;  Score 1629;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 7.2e-133;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 6
AAM93905
ID   AAM93905 standard; Protein; 310 AA.
XX
AC   AAM93905;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human polypeptide, SEQ ID NO: 4051.
XX
KW   Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS   Homo sapiens.
XX
PN   EP1130094-A2.
XX
PD   05-SEP-2001.
XX
PF   07-JUL-2000; 2000EP-0114089.
XX
PR   08-JUL-1999;   99JP-0194486.
PR   11-JAN-2000; 2000JP-0118774.
PR   02-MAY-2000; 2000JP-0183765.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI   Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR   WPI; 2001-524255/58.
DR   N-PSDB; AAK94867.
XX
PT   830 Primers useful for synthesizing full length cDNA clones and their
PT   use in genetic manipulation -
XX
PS   Claim 8; SEQ ID NO 4051; 1380pp + sequence listing; English.
XX
CC   The invention relates to primers for synthesising full length cDNA
CC   clones. 830 cDNA molecules encoding a human protein have been
CC   isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC   molecules have been determined. Primers for synthesising the full length
CC   cDNA are useful for clarifying the function of the protein encoded by
CC   the cDNA. The full length clones were obtained by construction of full
CC   length enriched cDNA libraries that were synthesised by the oligo-capping
CC   method. The primers enable the production of the full length cDNA easily
CC   without any special methods. The present sequence is a polypeptide
CC   encoded by a full length human cDNA of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in CD-ROM format directly from EPO.
XX
SQ   Sequence   310 AA;

  Query Match             99.6%;  Score 1629;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 7.2e-133;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 7
AAU12440
ID   AAU12440 standard; Protein; 310 AA.
XX
AC   AAU12440;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human PRO1868 polypeptide sequence.
XX
KW   Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW   breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW   cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW   adipocyte; A-peptide; factor VIIA; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200140466-A2.
XX
PD   07-JUN-2001.
XX
PF   01-DEC-2000; 2000WO-US32678.
XX
```

PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 09-DEC-1999; 99US-0170262.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 30-DEC-1999; 99WO-US31243.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 10-NOV-2000; 2000WO-US30873.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2001-408281/43.
DR N-PSDB; AAS21512.
XX
PT Isolated, secretory and transmembrane PRO polypeptide used to detect
PT other PRO polypeptides, link bioactive molecules to cells expressing
PT PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT lung, breast, prostate, cervical -
XX
PS Claim 12; Fig 538; 813pp; English.
XX
CC AAU12172-AAU12446 represent novel human secretory and transmembrane
CC PRO polypeptides. The PRO polypeptides are useful to detect other
CC PRO polypeptides, to link bioactive molecules to cells expressing
CC PRO polypeptides, to modulate biological activities of cells expressing
CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample.
CC Some of the 275 sequences are also useful to stimulate the release of
CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC proliferation or differentiation of chondrocytes, the proliferation or
CC gene expression in pericyte cells, the release of proteoglycans from
CC cartilage, the proliferation of inner ear utricular supporting cells or
CC of T-lymphocytes, the release of a cytokine from peripheral blood
CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC to factor VIIA. The PRO polypeptides can be used in assays to identify
CC molecules involved in binding interactions. The polynucleotides encoding
CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 22; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy 61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy 121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy 181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db 181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy 241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy 301 DFRHKSSFVI 310
||||||||||
Db 301 DFRHKSSFVI 310

RESULT 8
AAB80272
ID AAB80272 standard; Protein; 310 AA.
XX
AC AAB80272;
XX
DT 24-APR-2001 (first entry)
XX
DE Human PRO1868 protein.
XX
KW Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
KW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW ischaemia; inflammation.
XX
OS Homo sapiens.
XX
PN WO200104311-A1.
XX
PD 18-JAN-2001.
XX
PF 22-FEB-2000; 2000WO-US04414.
XX
PR 07-JUL-1999; 99US-0143048.
PR 26-JUL-1999; 99US-0145698.
PR 28-JUL-1999; 99US-0146222.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 05-JAN-2000; 99WO-US00219.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP,, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2001-081051/09.
DR N-PSDB; AAF72433.

```
XX
PT   Sixty one nucleic acids encoding PRO polypeptides which are useful in
PT   the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung
PT   squamous cell carcinoma) and neurodegenerative diseases (e.g.
PT   Alzheimer's disease) -
XX
PS   Claim 1; Fig 124; 393pp; English.
XX
CC   The present sequence is one of sixty one novel secreted and
CC   transmembrane PRO polypeptides. The PRO polypeptides are
CC   useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
CC   squamous cell carcinoma), gastrointestinal disorders (e.g.
CC   enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
CC   Parkinson's disease), wound repair, cardiovascular disorders (e.g.
CC   endometrial bleeding angiogenesis, ischaemias such as coronary
CC   ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma,
CC   rheumatoid arthritis, multiple sclerosis), infertility, AIDS and
CC   diabetes and retinal disorders such as retinitis pigmentosum.
CC   The PRO nucleic acids have applications in molecular biology, including
CC   use as hybridization probes, and in chromosome and gene mapping.
XX
SQ   Sequence   310 AA;

  Query Match             99.6%;  Score 1629;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 7.2e-133;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 9
AAB80383
ID   AAB80383 standard; protein; 310 AA.
XX
AC   AAB80383;
XX
DT   24-APR-2001  (first entry)
XX
DE   Secreted protein encoded by gene #13.
XX
KW   Secreted protein; human; autoimmune; hyperproliferation;
KW   cardiovascular; cerebrovascular; infection; food.
XX
OS   Homo sapiens.
XX
PN   WO200107459-A1.
XX
PD   01-FEB-2001.
XX
PF   20-JUL-2000; 2000WO-US19735.
XX
PR   23-JUL-1999;   99US-0145220.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Ebner R,  Duan RD,  Ni J,  Soppet DR,  Moore PA;
PI   Shi Y,  Lafleur DW,  Olsen HS,  Birse CE,  Komatsoulis GA;
XX
DR   WPI; 2001-123261/13.
XX
PT   New isolated nucleic acid encoding 29 secreted proteins, for
PT   diagnosing, preventing and treating e.g. autoimmune,
PT   hyperproliferative, cardiovascular, and ocular diseases or disorders
PT   and microorganism infections  -
XX
PS   Claim 11; Page 538-539; 601pp; English.
XX
CC   The present invention relates to 29 human secreted proteins. The
CC   invention is used to prevent autoimmune diseases e.g. rheumatoid
CC   arthritis, hyperproliferative disorders e.g. neoplasms of the
CC   breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC   cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
CC   nervous system disorders e.g. Alzheimer's disease, infections
CC   caused by bacteria, viruses and fungi and ocular disorders e.g.
CC   corneal infection. Also used in food preparations.
XX
SQ   Sequence   310 AA;

  Query Match             99.6%;  Score 1629;  DB 22;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 7.2e-133;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 10
AAB80408
ID   AAB80408 standard; protein; 310 AA.
XX
AC   AAB80408;
XX
DT   24-APR-2001  (first entry)
XX
DE   Secreted protein encoded by gene #38.
XX
KW   Secreted protein; human; autoimmune; hyperproliferation;
KW   cardiovascular; cerebrovascular; infection; food.
XX
OS   Homo sapiens.
XX
PN   WO200107459-A1.
XX
```

PD 01-FEB-2001.
XX
PF 20-JUL-2000; 2000WO-US19735.
XX
PR 23-JUL-1999; 99US-0145220.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Ebner R, Duan RD, Ni J, Soppet DR, Moore PA;
PI Shi Y, Lafleur DW, Olsen HS, Birse CE, Komatsoulis GA;
XX
DR WPI; 2001-123261/13.
XX
PT New isolated nucleic acid encoding 29 secreted proteins, for
PT diagnosing, preventing and treating e.g. autoimmune,
PT hyperproliferative, cardiovascular, and ocular diseases or disorders
PT and microorganism infections -
XX
PS Claim 11; Page 557-558; 601pp; English.
XX
CC The present invention relates to 29 human secreted proteins. The
CC invention is used to prevent autoimmune diseases e.g. rheumatoid
CC arthritis, hyperproliferative disorders e.g. neoplasms of the
CC breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections
CC caused by bacteria, viruses and fungi and ocular disorders e.g.
CC corneal infection. Also used in food preparations.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 22; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 11
AAB80409
ID AAB80409 standard; protein; 310 AA.
XX
AC AAB80409;
XX
DT 24-APR-2001 (first entry)
XX
DE Secreted protein encoded by gene #39.
XX
KW Secreted protein; human; autoimmune; hyperproliferation;
KW cardiovascular; cerebrovascular; infection; food.
XX

OS Homo sapiens.
XX
PN WO200107459-A1.
XX
PD 01-FEB-2001.
XX
PF 20-JUL-2000; 2000WO-US19735.
XX
PR 23-JUL-1999; 99US-0145220.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Ebner R, Duan RD, Ni J, Soppet DR, Moore PA;
PI Shi Y, Lafleur DW, Olsen HS, Birse CE, Komatsoulis GA;
XX
DR WPI; 2001-123261/13.
XX
PT New isolated nucleic acid encoding 29 secreted proteins, for
PT diagnosing, preventing and treating e.g. autoimmune,
PT hyperproliferative, cardiovascular, and ocular diseases or disorders
PT and microorganism infections -
XX
PS Claim 11; Page 559-560; 601pp; English.
XX
CC The present invention relates to 29 human secreted proteins. The
CC invention is used to prevent autoimmune diseases e.g. rheumatoid
CC arthritis, hyperproliferative disorders e.g. neoplasms of the
CC breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections
CC caused by bacteria, viruses and fungi and ocular disorders e.g.
CC corneal infection. Also used in food preparations.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 22; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 12
ABG31401
ID ABG31401 standard; Protein; 310 AA.
XX
AC ABG31401;
XX
DT 29-NOV-2002 (first entry)
XX
DE Human PRO1868 polypeptide.

```
XX
KW   Human; secreted and transmembrane polypeptide; PRO polypeptide;
KW   T-lymphocyte proliferation; inflammatory disease; rheumatoid arthritis;
KW   inflammatory bowel disease; Sjogren's syndrome; thyroiditis;
KW   autoimmune haemolytic anaemia; diabetes mellitus; multiple sclerosis;
KW   hepatitis; contact dermatitis; allergic disease; psoriasis; virucide;
KW   immune related disease; kidney disease; antiinflammatory; antithyroid;
KW   antirheumatic; antiarthritic; immunosuppressive; antianaemic;
KW   antidiabetic; neuroprotective; hepatotropic; antiinflammatory;
KW   dermatological; antiallergic; antipsoriatic; PRO1868.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..30
FT                   /label= Signal_peptide
FT   Modified-site   26..31
FT                   /note= "N-myristoylation site"
FT   Protein         31..310
FT                   /label= Mature_PRO1868
FT   Modified-site   69..77
FT                   /note= "Tyrosine kinase phosphorylation site"
FT   Modified-site   104..107
FT                   /note= "N-glycosylation site"
FT   Modified-site   106..109
FT                   /note= "Casein kinase II phosphorylation site"
FT   Modified-site   107..110
FT                   /note= "cAMP- and cGMP-dependent protein kinase
FT                         phosphorylation site"
FT   Modified-site   192..195
FT                   /note= "N-glycosylation site"
FT   Modified-site   215..220
FT                   /note= "N-myristoylation site"
FT   Modified-site   226..231
FT                   /note= "N-myristoylation site"
FT   Domain          243..263
FT                   /label= Transmembrane_domain
FT   Modified-site   243..248
FT                   /note= "N-myristoylation site"
FT   Modified-site   244..249
FT                   /note= "N-myristoylation site"
FT   Modified-site   262..267
FT                   /note= "N-myristoylation site"
FT   Modified-site   296..299
FT                   /note= "Casein kinase II phosphorylation site"
XX
PN   US2002098507-A1.
XX
PD   25-JUL-2002.
XX
PF   27-DEC-2001; 2001US-0033326.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   02-MAR-2000; 2000WO-US05841.
PR   30-MAR-2000; 2000WO-US08439.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   01-DEC-2000; 2000WO-US32678.
PR   16-DEC-1998;   98US-113145P.
PR   22-DEC-1998;   98US-113511P.
PR   12-JAN-1999;   99US-115558P.
PR   12-JAN-1999;   99US-115565P.
PR   12-JAN-1999;   99US-115733P.
PR   09-FEB-1999;   99US-119341P.
PR   10-FEB-1999;   99US-119537P.
PR   12-FEB-1999;   99US-119965P.
PR   29-OCT-1999;   99US-162506P.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Botstein D,  Desnoyers L,  Ferrara N,  Fong S,  Gao W,  Goddard A;
PI   Gurney AL,  Pan J,  Roy MA,  Stewart TA,  Tumas D,  Watanabe CK;
PI   Wood WI;
XX
DR   WPI; 2002-673823/72.
DR   N-PSDB; ABS53477.
XX
PT   Novel PRO polypeptides and nucleic acids encoding the polypeptides,
PT   useful for preparing a medicament for the treatment of inflammatory and
PT   immune related disorders -
XX
PS   Claim 12; Fig 14; 125pp; English.
XX
CC   The present invention relates to the isolation of novel human
CC   secreted and transmembrane polypeptides, designated PRO polypeptides,
CC   and the polynucleotide sequences encoding them. The PRO polypeptides
CC   of the invention include PRO1800, PRO539, PRO982, PRO1434, PRO1863,
CC   PRO1917, PRO1868, PRO3434 and PRO1927. The PRO polypeptides can
CC   inhibit the stimulation of T-lymphocyte proliferation. The PRO
CC   polypeptides are useful for the diagnosis and treatment of inflammatory
CC   diseases (e.g. inflammatory bowel disease, rheumatoid arthritis,
CC   Sjogren's syndrome, autoimmune haemolytic anaemia, thyroiditis, diabetes
CC   mellitus, multiple sclerosis, hepatitis, contact dermatitis, allergic
CC   diseases and psoriasis), immune related diseases, and kidney diseases
CC   in humans. The present sequence represents human PRO1868 polypeptide.
XX
SQ   Sequence   310 AA;

  Query Match             99.6%;  Score 1629;  DB 23;  Length 310;
  Best Local Similarity   99.7%;  Pred. No. 7.2e-133;
  Matches  309;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310


RESULT 13
ABG91361
ID   ABG91361 standard; Protein; 310 AA.
XX
AC   ABG91361;
XX
DT   29-NOV-2002  (first entry)
XX
DE   Novel human secreted protein #7.
XX
KW   Human; secreted protein; transmembrane protein; gene mapping;
KW   transgenic; immunogenic.
XX
OS   Homo sapiens.
XX
```

PN US2002098505-A1.
XX
PD 25-JUL-2002.
XX
PF 28-DEC-2001; 2001US-0033246.
XX
PR 02-JUN-1999; 99WO-US12252.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 02-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US08439.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 01-DEC-2000; 2000WO-US32678.
PR 16-DEC-1998; 98US-113145P.
PR 22-DEC-1998; 98US-113511P.
PR 12-JAN-1999; 99US-115558P.
PR 12-JAN-1999; 99US-115565P.
PR 12-JAN-1999; 99US-115733P.
PR 09-FEB-1999; 99US-119341P.
PR 10-FEB-1999; 99US-119537P.
PR 12-FEB-1999; 99US-119965P.
PR 29-OCT-1999; 99US-162506P.
XX
PA (GETH) GENENTECH INC.
XX
PI Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
PI Wood WI;
XX
DR WPI; 2002-665999/71.
DR N-PSDB; ABS67460.
XX
PT New human secreted and transmembrane (PRO) polypeptides, useful for
PT treating conditions requiring PRO polypeptides, for screening PRO
PT antagonists and agonists useful as drug candidates -
XX
PS Claim 12; Figure 14; 125pp; English.
XX
CC The invention relates to new human secreted and transmembrane proteins
CC (PRO) and nucleic acids of the invention. The polypeptides can be
CC administered therapeutically, especially by expressing encoding
CC polynucleotides, e.g. in therapeutic compositions. They can be used to
CC screen for PRO polypeptide antagonists and agonists useful to identify
CC drug candidates. They can also be used to produce antibodies, useful to
CC detect PRO polypeptides (e.g. diagnostically), purify PRO polypeptides or
CC therapeutically (e.g. as antagonists or to target and/or deliver
CC cytotoxic agents). The polynucleotides are useful therapeutically e.g. to
CC produce antisense sequences to inhibit polypeptide production. They can
CC be used to produce probes and primers useful to detect or isolate
CC sequences encoding PRO polypeptides or similar sequences e.g. variants or
CC sequences from other species. They are also useful for gene mapping and
CC to generate transgenic animals. ABG91355-ABG91363 represent human PRO
CC amino acid sequences of the invention.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 23; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 14
ABG92709
ID ABG92709 standard; Protein; 310 AA.
XX
AC ABG92709;
XX
DT 18-NOV-2002 (first entry)
XX
DE Human secreted protein PRO1868.
XX
KW Human; secreted and transmembrane protein; PRO1800; PRO539;
KW PRO982; PRO1434; PRO1863; PRO1917; PRO1868; PRO3434; PRO1927;
KW inflammatory disorder; immune related disease; rheumatoid arthritis;
KW systemic lupus erythematosus; systemic sclerosis; thyroiditis;
KW autoimmune haemolytic anaemia; diabetes mellitus; infectious hepatitis;
KW psoriasis; allergic disease of the lung; graft-versus host disease;
KW tumour; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002098506-A1.
XX
PD 25-JUL-2002.
XX
PF 27-DEC-2001; 2001US-0033301.
XX
PR 04-AUG-1998; 98US-095325P.
PR 16-DEC-1998; 98US-112851P.
PR 16-DEC-1998; 98US-113145P.
PR 22-DEC-1998; 98US-113511P.
PR 12-JAN-1999; 99US-115558P.
PR 12-JAN-1999; 99US-115565P.
PR 12-JAN-1999; 99US-115733P.
PR 09-FEB-1999; 99US-119341P.
PR 10-FEB-1999; 99US-119537P.
PR 12-FEB-1999; 99US-119965P.
PR 29-OCT-1999; 99US-162506P.
PR 02-JUN-1999; 99WO-US12252.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 02-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US08439.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 01-DEC-2000; 2000WO-US32678.
XX
PA (GETH) GENENTECH INC.
XX
PI Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
PI Wood WI;
XX
DR WPI; 2002-690475/74.
DR N-PSDB; ABS68392.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides

PT useful for diagnosis and treatment of inflammatory disorders and
PT immune-related diseases, and identifying modulators -
XX
PS Claim 12; Fig 14; 125pp; English.
XX
CC The invention relates to an isolated polypeptide having at least 80%
CC amino acid sequence identity to secreted and transmembrane polypeptides
CC PRO1800, PRO539, PRO982, PRO1434, PRO1863, PRO1917, PRO1868, PRO3434 or
CC PRO1927 and their encoding nucleic acids. Also included are vectors, host
CC cells and antibodies against PRO polypeptides. PRO proteins are useful
CC for identifying modulators of the polypeptide. PRO1868 useful for the
CC diagnosis and treatment of inflammatory and immune related diseases
CC including systemic lupus erythematosus, rheumatoid arthritis, systemic
CC sclerosis, autoimmune haemolytic anaemia, thyroiditis, diabetes mellitus,
CC infectious hepatitis, psoriasis, allergic diseases of the lung and
CC graft-versus host disease and tumours. Pro nucleic acids are useful for
CC constructing hybridisation probes for mapping the gene that encodes that
CC PRO and for the genetic analysis of individuals with genetic disorders,
CC and for generating transgenic animals which are useful in the development
CC and screening of therapeutically useful reagents. PRO nucleic acids are
CC also useful for gene therapy, chromosome identification, and tissue
CC typing. PRO proteins are useful as molecular weight markers for protein
CC electrophoresis purposes. The anti-PRO antibodies are useful in
CC diagnostic assays for PRO, e.g. detecting its expression in specific
CC cells, tissues or serum and for affinity purification of PRO.
CC The present sequence represents a PRO protein.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 23; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

RESULT 15
ABG65296
ID ABG65296 standard; Protein; 310 AA.
XX
AC ABG65296;
XX
DT 27-AUG-2002 (first entry)
XX
DE Human albumin fusion protein #1971.
XX
KW Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW human serum albumin; HSA; cancer; reproductive disorder;
KW digestive disorder; immune disorder; endocrine disorder;
KW haematopoietic disorder; neural disorder; connective disorder;
KW cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW osteopathic; antiarthritic.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200177137-A1.
XX
PD 18-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US11988.
XX
PR 12-APR-2000; 2000US-229358P.
PR 25-APR-2000; 2000US-199384P.
PR 21-DEC-2000; 2000US-256931P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Haseltine WA;
XX
DR WPI; 2002-010886/01.
XX
PT New fusion protein for treating disease e.g. diabetes comprises an
PT albumin fused to a therapeutic protein -
XX
PS Claim 1; Page 1893-1894; 2102pp; English.
XX
CC The present invention relates to albumin fusion proteins comprising a
CC therapeutic protein X and human albumin (HA, also known as human serum
CC albumin, HSA). The proteins are useful for treating a disease or
CC disorder that may be modulated by therapeutic protein X. The albumin
CC extends the shelf-life of protein X, and may increase its biological
CC in vitro/in vivo activity. The protein is useful for treating and
CC diagnosing disorders such as cancer, reproductive disorders, digestive
CC disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders
CC (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders
CC (e.g. diabetes), haematopoietic disorders, neural disorders
CC (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,
CC encephalomyelitis, meningitis, schizophrenia), and connective disorders
CC (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin
CC fusion proteins of the invention.
XX
SQ Sequence 310 AA;

Query Match 99.6%; Score 1629; DB 23; Length 310;
Best Local Similarity 99.7%; Pred. No. 7.2e-133;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MALRRPPRLRLCARLPDFFLLLLFRGCLIGAVNLKSSNRTPVVQEFESVELSCIITDSQT 60

Qy         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SDPRIEWKKIQDEQTTYVFFDNKIQGDLAGRAEILGKTSLKIWNVTRRDSALYRCEVVAR 120

Qy        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 NDRKEIDEIVIELTVQVKPVTPVCRVPKAVPVGKMATLHCQESEGHPRPHYSWYRNDVPL 180

Qy        181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        181 PTDSRANPRFRNSSFHLNSETGTLVFTAVHKDDSGQYYCIASNDAGSARCEEQEMEVYDL 240

Qy        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 NIGGIIGGVLVVLAVLALITLGICCAYRRGYFINNKQDGESYKNPGKPDGVNYIRTDEEG 300

Qy        301 DFRHKSSFVI 310
              ||||||||||
Db        301 DFRHKSSFVI 310
```

Search completed: December 15, 2003, 14:51:09
Job time : 43 secs